HEALTH● LOW1d ago · Oct 12, 2026, 2:20 PM
Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases
Seeking Alpha Tech · global
Mirum's drug Livmarli successfully met its primary objective in a Phase 3 clinical trial for treating itch associated with rare liver diseases. This represents a significant step in the development of a potential new treatment for these conditions.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH56m agoAt NIFST AGM: NAFDAC DG charges food scientists on food safety, qualityVanguard NigeriaHEALTH1h agoAMR: FG warns of growing threat of drug-resistant infectionsVanguard NigeriaHEALTH1h agoUttar Pradesh MBBS doctors protest over pay disparity, pending salary arrears; announce work boycottThe HinduHEALTH1h agoDoctors discuss Pope Leo's lung cancer diagnosisCBS News